nodes	percent_of_prediction	percent_of_DWPC	metapath
Aminosalicylic Acid—MPO—urinary bladder cancer	0.366	0.728	CbGaD
Aminosalicylic Acid—PTGS2—urinary bladder cancer	0.137	0.273	CbGaD
Aminosalicylic Acid—MPO—Carboplatin—urinary bladder cancer	0.114	0.373	CbGbCtD
Aminosalicylic Acid—MPO—Cisplatin—urinary bladder cancer	0.0976	0.318	CbGbCtD
Aminosalicylic Acid—PTGS2—Cisplatin—urinary bladder cancer	0.0337	0.11	CbGbCtD
Aminosalicylic Acid—PTGS2—Etoposide—urinary bladder cancer	0.0331	0.108	CbGbCtD
Aminosalicylic Acid—PTGS1—Etoposide—urinary bladder cancer	0.028	0.0912	CbGbCtD
Aminosalicylic Acid—CHUK—prostate gland—urinary bladder cancer	0.00343	0.119	CbGeAlD
Aminosalicylic Acid—CHUK—epithelium—urinary bladder cancer	0.00252	0.0871	CbGeAlD
Aminosalicylic Acid—CHUK—renal system—urinary bladder cancer	0.00234	0.0808	CbGeAlD
Aminosalicylic Acid—ALOX5—prostate gland—urinary bladder cancer	0.00193	0.0668	CbGeAlD
Aminosalicylic Acid—CHUK—female reproductive system—urinary bladder cancer	0.00187	0.0647	CbGeAlD
Aminosalicylic Acid—ALOX5—smooth muscle tissue—urinary bladder cancer	0.00137	0.0473	CbGeAlD
Aminosalicylic Acid—ALOX5—urethra—urinary bladder cancer	0.00129	0.0447	CbGeAlD
Aminosalicylic Acid—MPO—epithelium—urinary bladder cancer	0.0012	0.0415	CbGeAlD
Aminosalicylic Acid—MPO—renal system—urinary bladder cancer	0.00111	0.0385	CbGeAlD
Aminosalicylic Acid—CHUK—lymph node—urinary bladder cancer	0.00109	0.0378	CbGeAlD
Aminosalicylic Acid—ALOX5—female reproductive system—urinary bladder cancer	0.00105	0.0364	CbGeAlD
Aminosalicylic Acid—Mesalazine—MPO—urinary bladder cancer	0.000806	0.333	CrCbGaD
Aminosalicylic Acid—PTGS1—prostate gland—urinary bladder cancer	0.000775	0.0268	CbGeAlD
Aminosalicylic Acid—PTGS2—prostate gland—urinary bladder cancer	0.000741	0.0256	CbGeAlD
Aminosalicylic Acid—Mesalazine—PPARG—urinary bladder cancer	0.000716	0.295	CrCbGaD
Aminosalicylic Acid—PTGS1—seminal vesicle—urinary bladder cancer	0.000656	0.0227	CbGeAlD
Aminosalicylic Acid—PTGS2—seminal vesicle—urinary bladder cancer	0.000627	0.0217	CbGeAlD
Aminosalicylic Acid—ALOX5—lymph node—urinary bladder cancer	0.000617	0.0213	CbGeAlD
Aminosalicylic Acid—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.000575	0.00833	CcSEcCtD
Aminosalicylic Acid—PTGS1—epithelium—urinary bladder cancer	0.00057	0.0197	CbGeAlD
Aminosalicylic Acid—Abdominal pain—Valrubicin—urinary bladder cancer	0.000556	0.00805	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Valrubicin—urinary bladder cancer	0.000556	0.00805	CcSEcCtD
Aminosalicylic Acid—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000549	0.019	CbGeAlD
Aminosalicylic Acid—Anaemia—Mitomycin—urinary bladder cancer	0.000548	0.00795	CcSEcCtD
Aminosalicylic Acid—PTGS2—epithelium—urinary bladder cancer	0.000545	0.0188	CbGeAlD
Aminosalicylic Acid—Leukopenia—Mitomycin—urinary bladder cancer	0.000531	0.0077	CcSEcCtD
Aminosalicylic Acid—PTGS1—renal system—urinary bladder cancer	0.000528	0.0183	CbGeAlD
Aminosalicylic Acid—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000525	0.0181	CbGeAlD
Aminosalicylic Acid—MPO—lymph node—urinary bladder cancer	0.000522	0.018	CbGeAlD
Aminosalicylic Acid—Body temperature increased—Carboplatin—urinary bladder cancer	0.000515	0.00746	CcSEcCtD
Aminosalicylic Acid—PTGS2—renal system—urinary bladder cancer	0.000505	0.0175	CbGeAlD
Aminosalicylic Acid—PTGS2—urethra—urinary bladder cancer	0.000496	0.0172	CbGeAlD
Aminosalicylic Acid—Diarrhoea—Valrubicin—urinary bladder cancer	0.000481	0.00697	CcSEcCtD
Aminosalicylic Acid—Eruption—Methotrexate—urinary bladder cancer	0.000478	0.00692	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.000474	0.00687	CcSEcCtD
Aminosalicylic Acid—Dizziness—Valrubicin—urinary bladder cancer	0.000465	0.00674	CcSEcCtD
Aminosalicylic Acid—Anorexia—Mitomycin—urinary bladder cancer	0.000462	0.00669	CcSEcCtD
Aminosalicylic Acid—Encephalopathy—Methotrexate—urinary bladder cancer	0.000458	0.00663	CcSEcCtD
Aminosalicylic Acid—Vomiting—Valrubicin—urinary bladder cancer	0.000447	0.00648	CcSEcCtD
Aminosalicylic Acid—Eruption—Epirubicin—urinary bladder cancer	0.000447	0.00647	CcSEcCtD
Aminosalicylic Acid—Optic neuritis—Epirubicin—urinary bladder cancer	0.000447	0.00647	CcSEcCtD
Aminosalicylic Acid—Rash—Valrubicin—urinary bladder cancer	0.000443	0.00642	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Valrubicin—urinary bladder cancer	0.000443	0.00642	CcSEcCtD
Aminosalicylic Acid—Headache—Valrubicin—urinary bladder cancer	0.00044	0.00638	CcSEcCtD
Aminosalicylic Acid—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.00043	0.00624	CcSEcCtD
Aminosalicylic Acid—PTGS1—female reproductive system—urinary bladder cancer	0.000423	0.0146	CbGeAlD
Aminosalicylic Acid—Decreased appetite—Mitomycin—urinary bladder cancer	0.000421	0.0061	CcSEcCtD
Aminosalicylic Acid—Nausea—Valrubicin—urinary bladder cancer	0.000418	0.00605	CcSEcCtD
Aminosalicylic Acid—Optic neuritis—Doxorubicin—urinary bladder cancer	0.000413	0.00599	CcSEcCtD
Aminosalicylic Acid—Eruption—Doxorubicin—urinary bladder cancer	0.000413	0.00599	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Fluorouracil—urinary bladder cancer	0.00041	0.00594	CcSEcCtD
Aminosalicylic Acid—PTGS2—female reproductive system—urinary bladder cancer	0.000405	0.014	CbGeAlD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Cisplatin—urinary bladder cancer	0.000389	0.00563	CcSEcCtD
Aminosalicylic Acid—Diflunisal—PTGS2—urinary bladder cancer	0.000385	0.159	CrCbGaD
Aminosalicylic Acid—Body temperature increased—Mitomycin—urinary bladder cancer	0.000383	0.00555	CcSEcCtD
Aminosalicylic Acid—PTGS1—vagina—urinary bladder cancer	0.000383	0.0132	CbGeAlD
Aminosalicylic Acid—Jaundice—Thiotepa—urinary bladder cancer	0.000372	0.00539	CcSEcCtD
Aminosalicylic Acid—Dermatitis atopic—Epirubicin—urinary bladder cancer	0.000371	0.00538	CcSEcCtD
Aminosalicylic Acid—PTGS2—vagina—urinary bladder cancer	0.000366	0.0126	CbGeAlD
Aminosalicylic Acid—Agranulocytosis—Thiotepa—urinary bladder cancer	0.000356	0.00516	CcSEcCtD
Aminosalicylic Acid—Dermatitis atopic—Doxorubicin—urinary bladder cancer	0.000344	0.00498	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000339	0.0049	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Thiotepa—urinary bladder cancer	0.000336	0.00487	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Mitomycin—urinary bladder cancer	0.000331	0.0048	CcSEcCtD
Aminosalicylic Acid—Dizziness—Mitomycin—urinary bladder cancer	0.00032	0.00464	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Gemcitabine—urinary bladder cancer	0.000315	0.00456	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Fluorouracil—urinary bladder cancer	0.00031	0.00449	CcSEcCtD
Aminosalicylic Acid—Vomiting—Mitomycin—urinary bladder cancer	0.000308	0.00446	CcSEcCtD
Aminosalicylic Acid—Rash—Mitomycin—urinary bladder cancer	0.000305	0.00442	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Mitomycin—urinary bladder cancer	0.000305	0.00442	CcSEcCtD
Aminosalicylic Acid—Headache—Mitomycin—urinary bladder cancer	0.000303	0.0044	CcSEcCtD
Aminosalicylic Acid—Mesalazine—PTGS2—urinary bladder cancer	0.000302	0.125	CrCbGaD
Aminosalicylic Acid—Vasculitis—Methotrexate—urinary bladder cancer	0.000301	0.00436	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.0003	0.00434	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Thiotepa—urinary bladder cancer	0.000298	0.00432	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.000295	0.00427	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Cisplatin—urinary bladder cancer	0.000294	0.00425	CcSEcCtD
Aminosalicylic Acid—Nausea—Mitomycin—urinary bladder cancer	0.000288	0.00417	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000285	0.00413	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000283	0.0041	CcSEcCtD
Aminosalicylic Acid—Anaemia—Thiotepa—urinary bladder cancer	0.000276	0.004	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Etoposide—urinary bladder cancer	0.000269	0.0039	CcSEcCtD
Aminosalicylic Acid—Jaundice—Etoposide—urinary bladder cancer	0.000267	0.00387	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Thiotepa—urinary bladder cancer	0.000267	0.00387	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000265	0.00385	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Cisplatin—urinary bladder cancer	0.000263	0.00382	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Etoposide—urinary bladder cancer	0.000256	0.00371	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000252	0.00366	CcSEcCtD
Aminosalicylic Acid—PTGS1—lymph node—urinary bladder cancer	0.000248	0.00856	CbGeAlD
Aminosalicylic Acid—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000243	0.00352	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Etoposide—urinary bladder cancer	0.000241	0.0035	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000239	0.00346	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000238	0.00345	CcSEcCtD
Aminosalicylic Acid—PTGS2—lymph node—urinary bladder cancer	0.000237	0.00818	CbGeAlD
Aminosalicylic Acid—Skin disorder—Thiotepa—urinary bladder cancer	0.000237	0.00343	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Cisplatin—urinary bladder cancer	0.000234	0.00339	CcSEcCtD
Aminosalicylic Acid—Anorexia—Thiotepa—urinary bladder cancer	0.000232	0.00336	CcSEcCtD
Aminosalicylic Acid—Anaemia—Gemcitabine—urinary bladder cancer	0.000232	0.00336	CcSEcCtD
Aminosalicylic Acid—Flatulence—Cisplatin—urinary bladder cancer	0.000231	0.00334	CcSEcCtD
Aminosalicylic Acid—Anaemia—Fluorouracil—urinary bladder cancer	0.000228	0.00331	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.000226	0.00327	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Gemcitabine—urinary bladder cancer	0.000225	0.00326	CcSEcCtD
Aminosalicylic Acid—Vascular purpura—Epirubicin—urinary bladder cancer	0.000223	0.00323	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Fluorouracil—urinary bladder cancer	0.000221	0.0032	CcSEcCtD
Aminosalicylic Acid—Anaemia—Cisplatin—urinary bladder cancer	0.000216	0.00313	CcSEcCtD
Aminosalicylic Acid—Salicylic acid—PTGS2—urinary bladder cancer	0.000214	0.0884	CrCbGaD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000212	0.00308	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Thiotepa—urinary bladder cancer	0.000212	0.00307	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000211	0.00306	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00021	0.00305	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Etoposide—urinary bladder cancer	0.00021	0.00304	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Cisplatin—urinary bladder cancer	0.000209	0.00303	CcSEcCtD
Aminosalicylic Acid—Purpura—Epirubicin—urinary bladder cancer	0.000207	0.003	CcSEcCtD
Aminosalicylic Acid—Vascular purpura—Doxorubicin—urinary bladder cancer	0.000206	0.00299	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000204	0.00296	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000201	0.00291	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000201	0.00291	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.0002	0.00289	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000199	0.00289	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Gemcitabine—urinary bladder cancer	0.000199	0.00288	CcSEcCtD
Aminosalicylic Acid—Anaemia—Etoposide—urinary bladder cancer	0.000198	0.00287	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000198	0.00287	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000198	0.00286	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000197	0.00286	CcSEcCtD
Aminosalicylic Acid—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.000196	0.00283	CcSEcCtD
Aminosalicylic Acid—Anorexia—Gemcitabine—urinary bladder cancer	0.000195	0.00283	CcSEcCtD
Aminosalicylic Acid—Urticaria—Thiotepa—urinary bladder cancer	0.000193	0.0028	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Thiotepa—urinary bladder cancer	0.000193	0.00279	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Thiotepa—urinary bladder cancer	0.000193	0.00279	CcSEcCtD
Aminosalicylic Acid—Anorexia—Fluorouracil—urinary bladder cancer	0.000192	0.00278	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Etoposide—urinary bladder cancer	0.000192	0.00278	CcSEcCtD
Aminosalicylic Acid—Purpura—Doxorubicin—urinary bladder cancer	0.000192	0.00278	CcSEcCtD
Aminosalicylic Acid—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000189	0.00274	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000187	0.00271	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000187	0.00271	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Cisplatin—urinary bladder cancer	0.000185	0.00269	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000185	0.00267	CcSEcCtD
Aminosalicylic Acid—Anorexia—Cisplatin—urinary bladder cancer	0.000182	0.00264	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000181	0.00263	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000179	0.0026	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000178	0.00258	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000177	0.00256	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000175	0.00254	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000174	0.00252	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Epirubicin—urinary bladder cancer	0.000174	0.00252	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000171	0.00248	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Etoposide—urinary bladder cancer	0.00017	0.00246	CcSEcCtD
Aminosalicylic Acid—Anorexia—Etoposide—urinary bladder cancer	0.000167	0.00242	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Thiotepa—urinary bladder cancer	0.000167	0.00241	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Cisplatin—urinary bladder cancer	0.000166	0.00241	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000165	0.00239	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000162	0.00235	CcSEcCtD
Aminosalicylic Acid—Dizziness—Thiotepa—urinary bladder cancer	0.000161	0.00233	CcSEcCtD
Aminosalicylic Acid—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000161	0.00233	CcSEcCtD
Aminosalicylic Acid—Urticaria—Fluorouracil—urinary bladder cancer	0.00016	0.00232	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000159	0.00231	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Epirubicin—urinary bladder cancer	0.000156	0.00226	CcSEcCtD
Aminosalicylic Acid—Vomiting—Thiotepa—urinary bladder cancer	0.000155	0.00224	CcSEcCtD
Aminosalicylic Acid—Rash—Thiotepa—urinary bladder cancer	0.000154	0.00222	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Thiotepa—urinary bladder cancer	0.000153	0.00222	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000153	0.00222	CcSEcCtD
Aminosalicylic Acid—Headache—Thiotepa—urinary bladder cancer	0.000153	0.00221	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Etoposide—urinary bladder cancer	0.000152	0.0022	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000151	0.00219	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Cisplatin—urinary bladder cancer	0.000151	0.00219	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000151	0.00218	CcSEcCtD
Aminosalicylic Acid—Jaundice—Epirubicin—urinary bladder cancer	0.00015	0.00217	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000148	0.00215	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Methotrexate—urinary bladder cancer	0.000148	0.00214	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000146	0.00211	CcSEcCtD
Aminosalicylic Acid—Nausea—Thiotepa—urinary bladder cancer	0.000145	0.0021	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Methotrexate—urinary bladder cancer	0.000145	0.00209	CcSEcCtD
Aminosalicylic Acid—Weight decreased—Doxorubicin—urinary bladder cancer	0.000144	0.00209	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000143	0.00208	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000143	0.00207	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000141	0.00204	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00014	0.00203	CcSEcCtD
Aminosalicylic Acid—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000139	0.00202	CcSEcCtD
Aminosalicylic Acid—Urticaria—Etoposide—urinary bladder cancer	0.000139	0.00201	CcSEcCtD
Aminosalicylic Acid—Jaundice—Doxorubicin—urinary bladder cancer	0.000139	0.00201	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Etoposide—urinary bladder cancer	0.000138	0.002	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Etoposide—urinary bladder cancer	0.000138	0.002	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Epirubicin—urinary bladder cancer	0.000138	0.002	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000138	0.002	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000136	0.00197	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Epirubicin—urinary bladder cancer	0.000135	0.00196	CcSEcCtD
Aminosalicylic Acid—Dizziness—Fluorouracil—urinary bladder cancer	0.000133	0.00193	CcSEcCtD
Aminosalicylic Acid—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000133	0.00192	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Cisplatin—urinary bladder cancer	0.000131	0.00189	CcSEcCtD
Aminosalicylic Acid—Vomiting—Gemcitabine—urinary bladder cancer	0.00013	0.00189	CcSEcCtD
Aminosalicylic Acid—Rash—Gemcitabine—urinary bladder cancer	0.000129	0.00187	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Gemcitabine—urinary bladder cancer	0.000129	0.00187	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Etoposide—urinary bladder cancer	0.000129	0.00187	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Methotrexate—urinary bladder cancer	0.000128	0.00186	CcSEcCtD
Aminosalicylic Acid—Headache—Gemcitabine—urinary bladder cancer	0.000128	0.00186	CcSEcCtD
Aminosalicylic Acid—Vomiting—Fluorouracil—urinary bladder cancer	0.000128	0.00186	CcSEcCtD
Aminosalicylic Acid—Hepatitis—Doxorubicin—urinary bladder cancer	0.000128	0.00185	CcSEcCtD
Aminosalicylic Acid—Rash—Fluorouracil—urinary bladder cancer	0.000127	0.00184	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Fluorouracil—urinary bladder cancer	0.000127	0.00184	CcSEcCtD
Aminosalicylic Acid—Headache—Fluorouracil—urinary bladder cancer	0.000126	0.00183	CcSEcCtD
Aminosalicylic Acid—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000126	0.00183	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Methotrexate—urinary bladder cancer	0.000126	0.00182	CcSEcCtD
Aminosalicylic Acid—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000125	0.00181	CcSEcCtD
Aminosalicylic Acid—Nausea—Gemcitabine—urinary bladder cancer	0.000122	0.00176	CcSEcCtD
Aminosalicylic Acid—Vomiting—Cisplatin—urinary bladder cancer	0.000121	0.00176	CcSEcCtD
Aminosalicylic Acid—Rash—Cisplatin—urinary bladder cancer	0.00012	0.00174	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Cisplatin—urinary bladder cancer	0.00012	0.00174	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Epirubicin—urinary bladder cancer	0.00012	0.00174	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Etoposide—urinary bladder cancer	0.00012	0.00173	CcSEcCtD
Aminosalicylic Acid—Nausea—Fluorouracil—urinary bladder cancer	0.00012	0.00173	CcSEcCtD
Aminosalicylic Acid—Anaemia—Methotrexate—urinary bladder cancer	0.000119	0.00172	CcSEcCtD
Aminosalicylic Acid—Flatulence—Epirubicin—urinary bladder cancer	0.000118	0.00172	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Epirubicin—urinary bladder cancer	0.000118	0.0017	CcSEcCtD
Aminosalicylic Acid—Dizziness—Etoposide—urinary bladder cancer	0.000116	0.00168	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Methotrexate—urinary bladder cancer	0.000115	0.00167	CcSEcCtD
Aminosalicylic Acid—Nausea—Cisplatin—urinary bladder cancer	0.000113	0.00164	CcSEcCtD
Aminosalicylic Acid—Vomiting—Etoposide—urinary bladder cancer	0.000111	0.00161	CcSEcCtD
Aminosalicylic Acid—Malnutrition—Doxorubicin—urinary bladder cancer	0.000111	0.00161	CcSEcCtD
Aminosalicylic Acid—Anaemia—Epirubicin—urinary bladder cancer	0.000111	0.00161	CcSEcCtD
Aminosalicylic Acid—Rash—Etoposide—urinary bladder cancer	0.00011	0.0016	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Etoposide—urinary bladder cancer	0.00011	0.0016	CcSEcCtD
Aminosalicylic Acid—Headache—Etoposide—urinary bladder cancer	0.00011	0.00159	CcSEcCtD
Aminosalicylic Acid—Flatulence—Doxorubicin—urinary bladder cancer	0.00011	0.00159	CcSEcCtD
Aminosalicylic Acid—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000109	0.00158	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000109	0.00157	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Epirubicin—urinary bladder cancer	0.000108	0.00156	CcSEcCtD
Aminosalicylic Acid—Nausea—Etoposide—urinary bladder cancer	0.000104	0.00151	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000103	0.00149	CcSEcCtD
Aminosalicylic Acid—Anaemia—Doxorubicin—urinary bladder cancer	0.000103	0.00149	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000103	0.00149	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Methotrexate—urinary bladder cancer	0.000102	0.00147	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000102	0.00147	CcSEcCtD
Aminosalicylic Acid—Anorexia—Methotrexate—urinary bladder cancer	9.99e-05	0.00145	CcSEcCtD
Aminosalicylic Acid—Leukopenia—Doxorubicin—urinary bladder cancer	9.95e-05	0.00144	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Epirubicin—urinary bladder cancer	9.62e-05	0.00139	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Epirubicin—urinary bladder cancer	9.6e-05	0.00139	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Epirubicin—urinary bladder cancer	9.53e-05	0.00138	CcSEcCtD
Aminosalicylic Acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.4e-05	0.00136	CcSEcCtD
Aminosalicylic Acid—Anorexia—Epirubicin—urinary bladder cancer	9.35e-05	0.00135	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Methotrexate—urinary bladder cancer	9.11e-05	0.00132	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.05e-05	0.00131	CcSEcCtD
Aminosalicylic Acid—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.9e-05	0.00129	CcSEcCtD
Aminosalicylic Acid—Thrombocytopenia—Doxorubicin—urinary bladder cancer	8.88e-05	0.00129	CcSEcCtD
Aminosalicylic Acid—Skin disorder—Doxorubicin—urinary bladder cancer	8.81e-05	0.00128	CcSEcCtD
Aminosalicylic Acid—Anorexia—Doxorubicin—urinary bladder cancer	8.65e-05	0.00125	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Methotrexate—urinary bladder cancer	8.57e-05	0.00124	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Epirubicin—urinary bladder cancer	8.53e-05	0.00124	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.47e-05	0.00123	CcSEcCtD
Aminosalicylic Acid—Urticaria—Methotrexate—urinary bladder cancer	8.33e-05	0.00121	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Methotrexate—urinary bladder cancer	8.28e-05	0.0012	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Methotrexate—urinary bladder cancer	8.28e-05	0.0012	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.02e-05	0.00116	CcSEcCtD
Aminosalicylic Acid—Decreased appetite—Doxorubicin—urinary bladder cancer	7.89e-05	0.00114	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.83e-05	0.00113	CcSEcCtD
Aminosalicylic Acid—Urticaria—Epirubicin—urinary bladder cancer	7.79e-05	0.00113	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Epirubicin—urinary bladder cancer	7.75e-05	0.00112	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Epirubicin—urinary bladder cancer	7.75e-05	0.00112	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Methotrexate—urinary bladder cancer	7.72e-05	0.00112	CcSEcCtD
Aminosalicylic Acid—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.42e-05	0.00108	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Epirubicin—urinary bladder cancer	7.23e-05	0.00105	CcSEcCtD
Aminosalicylic Acid—Urticaria—Doxorubicin—urinary bladder cancer	7.21e-05	0.00104	CcSEcCtD
Aminosalicylic Acid—Body temperature increased—Doxorubicin—urinary bladder cancer	7.17e-05	0.00104	CcSEcCtD
Aminosalicylic Acid—Abdominal pain—Doxorubicin—urinary bladder cancer	7.17e-05	0.00104	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Methotrexate—urinary bladder cancer	7.17e-05	0.00104	CcSEcCtD
Aminosalicylic Acid—Dizziness—Methotrexate—urinary bladder cancer	6.93e-05	0.001	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Epirubicin—urinary bladder cancer	6.71e-05	0.000972	CcSEcCtD
Aminosalicylic Acid—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.69e-05	0.000969	CcSEcCtD
Aminosalicylic Acid—Vomiting—Methotrexate—urinary bladder cancer	6.66e-05	0.000965	CcSEcCtD
Aminosalicylic Acid—Rash—Methotrexate—urinary bladder cancer	6.61e-05	0.000957	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Methotrexate—urinary bladder cancer	6.6e-05	0.000956	CcSEcCtD
Aminosalicylic Acid—Headache—Methotrexate—urinary bladder cancer	6.57e-05	0.000951	CcSEcCtD
Aminosalicylic Acid—Dizziness—Epirubicin—urinary bladder cancer	6.49e-05	0.00094	CcSEcCtD
Aminosalicylic Acid—Vomiting—Epirubicin—urinary bladder cancer	6.24e-05	0.000903	CcSEcCtD
Aminosalicylic Acid—Nausea—Methotrexate—urinary bladder cancer	6.22e-05	0.000902	CcSEcCtD
Aminosalicylic Acid—Diarrhoea—Doxorubicin—urinary bladder cancer	6.21e-05	0.000899	CcSEcCtD
Aminosalicylic Acid—Rash—Epirubicin—urinary bladder cancer	6.18e-05	0.000896	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Epirubicin—urinary bladder cancer	6.18e-05	0.000895	CcSEcCtD
Aminosalicylic Acid—Headache—Epirubicin—urinary bladder cancer	6.14e-05	0.00089	CcSEcCtD
Aminosalicylic Acid—Dizziness—Doxorubicin—urinary bladder cancer	6e-05	0.000869	CcSEcCtD
Aminosalicylic Acid—Nausea—Epirubicin—urinary bladder cancer	5.83e-05	0.000844	CcSEcCtD
Aminosalicylic Acid—Vomiting—Doxorubicin—urinary bladder cancer	5.77e-05	0.000836	CcSEcCtD
Aminosalicylic Acid—Rash—Doxorubicin—urinary bladder cancer	5.72e-05	0.000829	CcSEcCtD
Aminosalicylic Acid—Dermatitis—Doxorubicin—urinary bladder cancer	5.72e-05	0.000828	CcSEcCtD
Aminosalicylic Acid—Headache—Doxorubicin—urinary bladder cancer	5.68e-05	0.000824	CcSEcCtD
Aminosalicylic Acid—Nausea—Doxorubicin—urinary bladder cancer	5.39e-05	0.000781	CcSEcCtD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—EGFR—urinary bladder cancer	3.63e-05	0.000406	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—EGFR—urinary bladder cancer	3.63e-05	0.000406	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	3.61e-05	0.000403	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—EGFR—urinary bladder cancer	3.6e-05	0.000402	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—KRAS—urinary bladder cancer	3.59e-05	0.000402	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	3.58e-05	0.0004	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—NQO1—urinary bladder cancer	3.57e-05	0.000399	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—ERBB2—urinary bladder cancer	3.57e-05	0.000399	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—EGFR—urinary bladder cancer	3.57e-05	0.000399	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—HDAC4—urinary bladder cancer	3.55e-05	0.000397	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—EGFR—urinary bladder cancer	3.55e-05	0.000397	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by SCF-KIT—HRAS—urinary bladder cancer	3.5e-05	0.000391	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.49e-05	0.00039	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.49e-05	0.00039	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—NAT1—urinary bladder cancer	3.48e-05	0.000389	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—GSTO2—urinary bladder cancer	3.48e-05	0.000389	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.46e-05	0.000387	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	3.46e-05	0.000387	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.44e-05	0.000385	CbGpPWpGaD
Aminosalicylic Acid—CHUK—BDNF signaling pathway—HRAS—urinary bladder cancer	3.44e-05	0.000384	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—PTEN—urinary bladder cancer	3.43e-05	0.000384	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—KRAS—urinary bladder cancer	3.43e-05	0.000383	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—KRAS—urinary bladder cancer	3.43e-05	0.000383	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—KRAS—urinary bladder cancer	3.43e-05	0.000383	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.42e-05	0.000383	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.42e-05	0.000382	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	3.41e-05	0.000381	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—KRAS—urinary bladder cancer	3.4e-05	0.00038	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—KRAS—urinary bladder cancer	3.37e-05	0.000377	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—EGFR—urinary bladder cancer	3.36e-05	0.000376	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—KRAS—urinary bladder cancer	3.36e-05	0.000375	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling of activated FGFR—HRAS—urinary bladder cancer	3.35e-05	0.000374	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PRSS3—urinary bladder cancer	3.32e-05	0.000371	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB4—HRAS—urinary bladder cancer	3.29e-05	0.000368	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—IL2—urinary bladder cancer	3.29e-05	0.000368	CbGpPWpGaD
Aminosalicylic Acid—PLA2G2E—Metabolism—EP300—urinary bladder cancer	3.27e-05	0.000366	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.25e-05	0.000364	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—SLC19A1—urinary bladder cancer	3.23e-05	0.000361	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.23e-05	0.000361	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—EGFR—urinary bladder cancer	3.22e-05	0.000359	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	3.18e-05	0.000356	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—KRAS—urinary bladder cancer	3.18e-05	0.000355	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—RBX1—urinary bladder cancer	3.16e-05	0.000353	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PRSS3—urinary bladder cancer	3.15e-05	0.000352	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signal transduction—HRAS—urinary bladder cancer	3.15e-05	0.000351	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	3.14e-05	0.00035	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR—HRAS—urinary bladder cancer	3.13e-05	0.00035	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by ERBB2—HRAS—urinary bladder cancer	3.12e-05	0.000348	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 signaling—HRAS—urinary bladder cancer	3.1e-05	0.000346	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—ENO2—urinary bladder cancer	3.07e-05	0.000343	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—urinary bladder cancer	3.06e-05	0.000341	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—CDKN1A—urinary bladder cancer	3.05e-05	0.000341	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—PTEN—urinary bladder cancer	3.04e-05	0.00034	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	3.04e-05	0.00034	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—KRAS—urinary bladder cancer	3.04e-05	0.00034	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.02e-05	0.000338	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—HDAC4—urinary bladder cancer	3.01e-05	0.000336	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—GSTP1—urinary bladder cancer	2.98e-05	0.000333	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—GLI1—urinary bladder cancer	2.98e-05	0.000333	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	2.98e-05	0.000332	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.92e-05	0.000326	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Fc epsilon receptor (FCERI) signaling—HRAS—urinary bladder cancer	2.92e-05	0.000326	CbGpPWpGaD
Aminosalicylic Acid—CHUK—DAP12 interactions—HRAS—urinary bladder cancer	2.92e-05	0.000326	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by FGFR in disease—HRAS—urinary bladder cancer	2.92e-05	0.000326	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—RBX1—urinary bladder cancer	2.91e-05	0.000326	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR—HRAS—urinary bladder cancer	2.89e-05	0.000323	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.88e-05	0.000322	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.87e-05	0.000321	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	2.87e-05	0.00032	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by EGFR in Cancer—HRAS—urinary bladder cancer	2.86e-05	0.00032	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—FGFR3—urinary bladder cancer	2.86e-05	0.000319	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by PDGF—HRAS—urinary bladder cancer	2.85e-05	0.000319	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	2.83e-05	0.000317	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—SRC—urinary bladder cancer	2.82e-05	0.000315	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—TYMS—urinary bladder cancer	2.77e-05	0.000309	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—FGFR3—urinary bladder cancer	2.74e-05	0.000306	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—NCOR1—urinary bladder cancer	2.74e-05	0.000306	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—GSTM1—urinary bladder cancer	2.74e-05	0.000306	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	2.71e-05	0.000302	CbGpPWpGaD
Aminosalicylic Acid—CHUK—B Cell Activation—HRAS—urinary bladder cancer	2.7e-05	0.000302	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.66e-05	0.000298	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—TYMP—urinary bladder cancer	2.66e-05	0.000297	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PRSS3—urinary bladder cancer	2.64e-05	0.000295	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—GPX1—urinary bladder cancer	2.62e-05	0.000293	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—JAG1—urinary bladder cancer	2.61e-05	0.000291	CbGpPWpGaD
Aminosalicylic Acid—CHUK—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	2.58e-05	0.000289	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.58e-05	0.000288	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—ERCC2—urinary bladder cancer	2.57e-05	0.000287	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.55e-05	0.000285	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	2.5e-05	0.000279	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.5e-05	0.000279	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.49e-05	0.000278	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—EGFR—urinary bladder cancer	2.47e-05	0.000276	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—CREBBP—urinary bladder cancer	2.43e-05	0.000272	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IFNA2—urinary bladder cancer	2.42e-05	0.00027	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—MTHFR—urinary bladder cancer	2.42e-05	0.00027	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—NAT2—urinary bladder cancer	2.4e-05	0.000268	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—LIG1—urinary bladder cancer	2.39e-05	0.000267	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	2.38e-05	0.000266	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.38e-05	0.000265	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—KRAS—urinary bladder cancer	2.34e-05	0.000261	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CDH1—urinary bladder cancer	2.32e-05	0.000259	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.31e-05	0.000258	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—S100B—urinary bladder cancer	2.29e-05	0.000256	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.12e-05	0.000236	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.11e-05	0.000236	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—RRM2—urinary bladder cancer	2.07e-05	0.000232	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.07e-05	0.000231	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—RBX1—urinary bladder cancer	2.04e-05	0.000228	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—ERBB2—urinary bladder cancer	2.04e-05	0.000227	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.03e-05	0.000226	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.02e-05	0.000226	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	2.02e-05	0.000226	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling by NGF—HRAS—urinary bladder cancer	1.99e-05	0.000222	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PPARG—urinary bladder cancer	1.96e-05	0.000219	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—ERBB2—urinary bladder cancer	1.96e-05	0.000218	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.93e-05	0.000215	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—ENO2—urinary bladder cancer	1.92e-05	0.000215	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—HPGDS—urinary bladder cancer	1.92e-05	0.000215	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TSC1—urinary bladder cancer	1.92e-05	0.000214	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.91e-05	0.000214	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.91e-05	0.000213	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—NAT2—urinary bladder cancer	1.91e-05	0.000213	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—NCOR1—urinary bladder cancer	1.9e-05	0.000212	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—CREBBP—urinary bladder cancer	1.88e-05	0.00021	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.86e-05	0.000208	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.83e-05	0.000205	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—JAG1—urinary bladder cancer	1.83e-05	0.000204	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—ENO2—urinary bladder cancer	1.82e-05	0.000203	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—ERCC2—urinary bladder cancer	1.79e-05	0.000199	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—CDKN1A—urinary bladder cancer	1.74e-05	0.000194	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—PTEN—urinary bladder cancer	1.74e-05	0.000194	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—RBX1—urinary bladder cancer	1.73e-05	0.000193	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.7e-05	0.00019	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—MTHFR—urinary bladder cancer	1.68e-05	0.000187	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—TERT—urinary bladder cancer	1.67e-05	0.000187	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—CDKN1A—urinary bladder cancer	1.67e-05	0.000187	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—PTEN—urinary bladder cancer	1.67e-05	0.000186	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—FGFR3—urinary bladder cancer	1.66e-05	0.000186	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—EP300—urinary bladder cancer	1.66e-05	0.000185	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.65e-05	0.000184	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—SRC—urinary bladder cancer	1.61e-05	0.00018	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.55e-05	0.000173	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—SRC—urinary bladder cancer	1.55e-05	0.000173	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—JAG1—urinary bladder cancer	1.54e-05	0.000173	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PTGS2—urinary bladder cancer	1.54e-05	0.000172	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—FGFR3—urinary bladder cancer	1.54e-05	0.000172	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.52e-05	0.00017	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.52e-05	0.00017	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.52e-05	0.000169	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.5e-05	0.000168	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.48e-05	0.000165	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—S100B—urinary bladder cancer	1.48e-05	0.000165	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.46e-05	0.000163	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CREBBP—urinary bladder cancer	1.42e-05	0.000158	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—EGFR—urinary bladder cancer	1.41e-05	0.000158	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CDH1—urinary bladder cancer	1.41e-05	0.000157	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—EGFR—urinary bladder cancer	1.36e-05	0.000151	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—PTEN—urinary bladder cancer	1.35e-05	0.00015	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—KRAS—urinary bladder cancer	1.33e-05	0.000149	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—NCOR1—urinary bladder cancer	1.33e-05	0.000149	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.31e-05	0.000146	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CREBBP—urinary bladder cancer	1.31e-05	0.000146	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.29e-05	0.000144	CbGpPWpGaD
Aminosalicylic Acid—ALOX5—Metabolism—EP300—urinary bladder cancer	1.28e-05	0.000143	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—KRAS—urinary bladder cancer	1.28e-05	0.000143	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.25e-05	0.00014	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.23e-05	0.000137	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.2e-05	0.000134	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.19e-05	0.000133	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.19e-05	0.000133	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—ERBB2—urinary bladder cancer	1.19e-05	0.000132	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—RHOA—urinary bladder cancer	1.18e-05	0.000132	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TERT—urinary bladder cancer	1.17e-05	0.000131	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.14e-05	0.000127	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Innate Immune System—HRAS—urinary bladder cancer	1.13e-05	0.000127	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—NCOR1—urinary bladder cancer	1.12e-05	0.000126	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.12e-05	0.000125	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—ERBB2—urinary bladder cancer	1.09e-05	0.000122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Adaptive Immune System—HRAS—urinary bladder cancer	1.09e-05	0.000122	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—FGFR3—urinary bladder cancer	1.08e-05	0.00012	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—IL2—urinary bladder cancer	1.07e-05	0.00012	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PTGS2—urinary bladder cancer	1.07e-05	0.00012	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—ERCC2—urinary bladder cancer	1.06e-05	0.000118	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.05e-05	0.000117	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—ESR1—urinary bladder cancer	1.04e-05	0.000117	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.04e-05	0.000116	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.03e-05	0.000115	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—CDKN1A—urinary bladder cancer	1.01e-05	0.000113	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—PTEN—urinary bladder cancer	1.01e-05	0.000113	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—MTHFR—urinary bladder cancer	9.94e-06	0.000111	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.92e-06	0.000111	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—TERT—urinary bladder cancer	9.91e-06	0.000111	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—EP300—urinary bladder cancer	9.64e-06	0.000108	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—TYMS—urinary bladder cancer	9.53e-06	0.000106	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—GSTM1—urinary bladder cancer	9.42e-06	0.000105	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—NCOR1—urinary bladder cancer	9.42e-06	0.000105	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—SRC—urinary bladder cancer	9.38e-06	0.000105	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—CDKN1A—urinary bladder cancer	9.36e-06	0.000105	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—PTEN—urinary bladder cancer	9.34e-06	0.000104	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CREBBP—urinary bladder cancer	9.16e-06	0.000102	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—FGFR3—urinary bladder cancer	9.1e-06	0.000102	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—IGF1—urinary bladder cancer	9.04e-06	0.000101	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—GPX1—urinary bladder cancer	9.02e-06	0.000101	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—EP300—urinary bladder cancer	8.9e-06	9.95e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—ERCC2—urinary bladder cancer	8.86e-06	9.89e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—SRC—urinary bladder cancer	8.66e-06	9.67e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PPARG—urinary bladder cancer	8.5e-06	9.5e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—MTHFR—urinary bladder cancer	8.33e-06	9.3e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—RHOA—urinary bladder cancer	8.28e-06	9.25e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—EGFR—urinary bladder cancer	8.22e-06	9.18e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—CREBBP—urinary bladder cancer	8.17e-06	9.13e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—KRAS—urinary bladder cancer	7.77e-06	8.67e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—MYC—urinary bladder cancer	7.76e-06	8.67e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CREBBP—urinary bladder cancer	7.74e-06	8.65e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—ERBB2—urinary bladder cancer	7.67e-06	8.57e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—EGFR—urinary bladder cancer	7.59e-06	8.48e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CXCL8—urinary bladder cancer	7.27e-06	8.12e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—KRAS—urinary bladder cancer	7.17e-06	8.01e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—RHOA—urinary bladder cancer	7.01e-06	7.83e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—IL2—urinary bladder cancer	6.95e-06	7.76e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CCND1—urinary bladder cancer	6.77e-06	7.57e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PPARG—urinary bladder cancer	6.75e-06	7.54e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PTGS2—urinary bladder cancer	6.69e-06	7.47e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Immune System—HRAS—urinary bladder cancer	6.6e-06	7.37e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MMP9—urinary bladder cancer	6.58e-06	7.35e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—CDKN1A—urinary bladder cancer	6.55e-06	7.32e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—PTEN—urinary bladder cancer	6.54e-06	7.3e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—CREBBP—urinary bladder cancer	6.49e-06	7.25e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—ERBB2—urinary bladder cancer	6.49e-06	7.25e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—EP300—urinary bladder cancer	6.24e-06	6.97e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Disease—HRAS—urinary bladder cancer	6.09e-06	6.81e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—SRC—urinary bladder cancer	6.06e-06	6.77e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—PTEN—urinary bladder cancer	5.83e-06	6.52e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS1—Metabolism—EP300—urinary bladder cancer	5.56e-06	6.22e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—CDKN1A—urinary bladder cancer	5.54e-06	6.19e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—PTEN—urinary bladder cancer	5.53e-06	6.18e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—MYC—urinary bladder cancer	5.43e-06	6.07e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—EGFR—urinary bladder cancer	5.31e-06	5.94e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—EP300—urinary bladder cancer	5.27e-06	5.89e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—SRC—urinary bladder cancer	5.13e-06	5.73e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—KRAS—urinary bladder cancer	5.02e-06	5.61e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—PTEN—urinary bladder cancer	4.63e-06	5.17e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—MYC—urinary bladder cancer	4.6e-06	5.13e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—EGFR—urinary bladder cancer	4.5e-06	5.02e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—TP53—urinary bladder cancer	4.46e-06	4.98e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Metabolism—EP300—urinary bladder cancer	4.42e-06	4.93e-05	CbGpPWpGaD
Aminosalicylic Acid—CHUK—Signaling Pathways—HRAS—urinary bladder cancer	4.27e-06	4.77e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—KRAS—urinary bladder cancer	4.25e-06	4.74e-05	CbGpPWpGaD
Aminosalicylic Acid—PTGS2—Disease—HRAS—urinary bladder cancer	3.61e-06	4.03e-05	CbGpPWpGaD
